Calreticulin–melatonin
An unexpected relationship
Manuel Macı
´
as
1
, Germaine Escames
1
, Josefa Leon
1
, Ana Coto
3
, Younes Sbihi
2
, Antonio Osuna
2
and Darı
´
o Acun
˜
a-Castroviejo
1
1
Departamento de Fisiologı
´
a and
2
Instituto de Biotecnologı
´
a, Universidad de Granada, Spain;
3
Departamento de Morfologı
´
a
y Biologı
´
a Celular, Facultad de Medicina, Universidad de Oviedo, Spain
Increasing evidence suggests that melatonin can exert some
effect at nuclear level. Previous experiments using binding
techniques clearly showed the existence of specific melatonin
binding sites in cell nucleus of rat liver. To further identify
these sites, nuclear extracts from rat hepatocytes were treated
with different percentages of ammonium sulfate and purified
by affinity chromatography. Subsequent ligand blot analysis
shows the presence of two polypeptides of 60 and
74 kDa that bind specifically to melatonin. N-Terminal
sequence analysis showed that the 60 kDa protein shares a
high homology with rat calreticulin, whereas the 74 kDa
protein shows no homology with any known protein. The
binding of melatonin to calreticulin was further charac-
terized incubating 2-[
125
I]melatonin with recombinant
calreticulin. Binding kinetics show a K
d
¼ 1.08 ± 0.2 n
M
and B
max
¼ 290 ± 34 fmolÆmg protein
)1
, compatible with
other binding sites of melatonin in the cell. The presence of
calreticulin was further identified by Western blot analysis,
and the lack of endoplasmic reticulum contamination in our
material was assessed by Western blot and immunostaining
with anti-calnexin Ig. The results suggest that calreticulin
may represent a new class of high-affinity melatonin binding
sites involved in some functions of the indoleamine including
genomic regulation.
Keywords: affinity chromatography; calreticulin; melatonin;
nuclear receptor purification; receptor binding.
Melatonin is a highly preserved molecule throughout
phylogeny. It appears in very ancient unicellular organisms
[1], remaining unchanged in multicellular species including
humans [2]. In mammals, the circadian rhythm of melatonin
is produced through a photoperiodic-dependent synthesis
by the pineal gland [3]. In turn, melatonin translates
photoperiodic information from clock and calendar mes-
sages, acting as an endogenous synchronizer of several
endocrine and nonendocrine rhythms [3]. This indoleamine
is also produced by a variety of other tissues [4]. Melatonin
exerts important regulatory influences on reproduction [5],
and on neuroendocrine [6] and immune systems [7].
Moreover, it also controls cellular proliferation through
regulatory effects on cell cycle kinetics [8], and prevents
apoptosis in several tissues [9]. Recent studies have also
focused on the antioxidant and free radical scavenging
properties of melatonin [10–13].
Except for the antioxidant, nonreceptor-mediated effects
of melatonin, the actions of the indoleamine suggest the
existence of specific receptors in the cell. Three related, but
distinct high affinity G
i
-protein-coupled melatonin receptor
subtypes have been cloned [14–17]. Membrane receptors for
melatonin are now classified as mt
1
,MT
2
and MT
3
.In
addition, biochemical and immunocytochemical studies in
different mammalian tissues have shown the presence and
accumulation of melatonin in the cell nuclei [18]. This
nuclear localization of melatonin can be related to its
described genomic effects including the regulation of the
mRNA levels for antioxidant enzymes and the inducible
isoform of nitric oxide synthase (iNOS) [19,20]. So far, no
responding gene could be directly linked to the activation of
membrane receptors by melatonin. However, a synergistic
effect of S 20098 and CGP 52608, two selective agonists of
the membrane and nuclear melatonin receptors, respect-
ively, on interleukin (IL)-6 production by human mononu-
clear cells has been shown [21]. Thus, to explain the nuclear
actions of the indoleamine it is reasonable to assume the
existence of a receptor in the nucleus of the cell.
Previous studies with [
3
H]melatonin showed the existence
of specific nuclear binding sites for melatonin [22]. Using
2-[
125
I]melatonin, the nuclear receptors for melatonin were
fully biochemical and pharmacologically characterized
[23,24]. The identification of melatonin as a ligand for the
ROR receptors [25,26] allowed its classification as a nuclear
effector. This viewpoint was further supported when it was
found that the nuclear receptor for melatonin represses
5-lipoxygenase gene expression in human B lymphocytes
[27]. Thus, it is reasonable to assume that nuclear melatonin
Correspondence to D. Acun
˜
a-Castroviejo, Departamento de
Fisiologı
´
a, Avenida de Madrid 11, E-18012 Granada, Spain.
Fax: + 34 958 246295, Tel.: + 34 958 246631,
E-mail: dacuna@ugr.es
Abbreviations: ER, endoplasmic reticulum; ERa, estrogen receptor
alpha; IL, interleukin; iNOS, inducible isoform of nitric oxide
synthase; NAS, N-acetylserotonin; PAP, peroxidase–
antiperoxidase; 4-P-PDOT, 4-phenyl 2-propionamidotetraline;
GST, glutathione S-transferase.
(Received 4 September 2002, revised 19 November 2002,
accepted 16 December 2002)
Eur. J. Biochem. 270, 832–840 (2003) Ó FEBS 2003 doi:10.1046/j.1432-1033.2003.03430.x
signaling is a basic mechanism for the various control
functions of the indoleamine.
The present work describes the purification and charac-
terization of two proteins from nuclei extracts of rat
hepatocytes that may represent a new class of melatonin
receptors. These polypeptides, with molecular masses of 74
and 60 kDa, were purified by ammonium sulfate precipi-
tation and affinity chromatography; characterized by SDS/
PAGE and Western blotting, and identified by their
N-terminal amino acid sequence. The search for sequence
similarities in protein databanks showed that the 60 kDa
protein is highly homologous to calreticulin, whereas the
74 kDa protein is a novel, unidentified protein.
Materials and methods
Materials
All reagents were of the highest purity available. Antibody
against melatonin (G/S/7048483) was obtained from Stock-
grand Ltd. (UK). Tris, sucrose, deoxyribonuclease (DNase),
ribonuclease (RNase), ammonium sulfate, EDTA/Na
2
,
phenylmethylsufonyl fluoride, leupeptin, pepstatin A,
Triton X-100, Tween 20, melatonin (N-acetyl-5-methoxy-
tryptamine), 6-hydroxymelatonin, N-acetylserotonin (NAS),
goat anti-rabbit immunoglobulin, peroxidase–antiperoxi-
dase complex, 3,3¢-diaminobenzidine tetrahydrochloride,
and all other chemicals and dyes were purchased from
Sigma-Aldrich Quı
´
mica (Madrid, Spain). 4-P-PDOT
(4-phenyl 2-propionamidotetraline) and luzindole (2-benzyl-
N-acetyptryptoamine) were obtained from Tocris Cookson
Ltd (Bristol, UK).
Isolation of liver nuclei and nuclear protein
fractionation
Nuclei were isolated from rat liver by the procedure described
elsewhere [28], with some modifications [24]. Briefly, rat livers
(0.9–1.2 g) were individually homogenized in 3 mL of buffer
A(10m
M
Tris/HCl, 0.3
M
sucrose, pH 7.4) with a glass/
Teflon homogenizer (10 strokes) and layered over 3 mL of
buffer A containing 0.4
M
sucrose. The samples were then
centrifuged at 2500 g for 10 min. The pellet was gently
resuspended without vortexing in 1 mL of buffer B (50 m
M
Tris/HCl, pH 7.4) and centrifuged again. All procedures
were carried out at 4 °C. The pellet containing pure, intact
nuclei was checked by electron microscopy for the quality of
the isolated nuclei (data not shown) [47].
The purified nuclei were resuspended in 1 mL of buffer B
and disrupted with a Polytron homogenizer (7 s, set point 9)
to obtain a crude nuclear extract. The crude nuclear extract
was further purified by resuspension in buffer B containing
protease inhibitors (5 m
M
EDTA-Na
2
,0.1m
M
phenyl-
methylsufonyl fluoride, 20 l
M
leupeptin and 2 l
M
pepstatin
A) and 0.1% Triton X-100. The homogenate was incubated
with DNase and RNase (25 lgÆmL
)1
), for 1 h at 37 °Cand
centrifuged to 48 000 g for 20 min at 4 °C. The proteins in
the supernatant (Triton X-100 soluble fraction) were preci-
pitated with different concentrations of ammonium sulfate
solutions (0–25, 25–45, and 45–65%) [29]. After gentle
stirring in an ice bath for 30 min, precipitate was collected by
centrifugation at 48 000 g for 30 min and resuspended in
buffer B. The resuspended sample was desalted in a Sephadex
G-25 gel filtration column (Amersham Pharmacia Biotech
Europe GmbH, Barcelona, Spain) pre-equilibrated with
buffer B containing 50% glycerol, and stored at ) 20 °C.
Affinity chromatography by melatonin–agarose
The hydroxyl group of 6-hydroxymelatonin was coupled to
the epoxide group of epoxy-activated Sepharose 6B (Amer-
sham Pharmacia Biotech Europe GmbH) [30] to yield a
resin, designated melatonin–agarose (Fig. 1). Briefly, epoxy-
activated Sepharose 6B was swelled and washed extensively
with deionized water, and 6-hydroxymelatonin was dis-
solved in freshly prepared 50% dioxane/50% 0.1
M
sodium
phosphate buffer, pH 8.7 (at higher pH values, 6-hydroxy-
melatonin was not stable). The 6-hydroxymelatonin solu-
tion was then mixed with the activated resin and sealed
under nitrogen. The mixture was agitated in darkness for
48–72 h at 32 °C. Ligand excess was eliminated washing the
gel with 50% dioxane, followed by bicarbonate (0.1
M
,
pH 8.0) and acetate (0.1
M
, pH 4.0) buffers. Unreacted
epoxide groups were then blocked by incubating the resin
with 1
M
ethanolamine for 16 h at 30 °C. The resin was
extensively washed with deionized water, and then with
bicarbonate and acetate buffers containing 500 m
M
NaCl
and 0.05% digitonin. The resin was resuspended in an equal
volume of 0.05% digitonin and stored at 4 °C.
Crude nuclear extracts and solubilized material were
separately incubated with melatonin–agarose (15 : 1 v/v) for
16–24 h at 4 °C under gentle agitation (100 r.p.m. on an
orbital shaker). The resin was then pelleted (1500 g)and
washed with 10 volumes of 0.05% digitonin until protein was
no longer detected in the final washed solution. The resin was
specifically eluted by incubating it with melatonin (10 l
M
;
one volume) for 6 h to 4 °C with moderate agitation. To
remove excess of ligand, the eluate was put over Sephadex
G-25 columns pre-equilibrated with 0.05% digitonin. The
final eluate was lyophilized and stored to )20 °C until
electrophoresis analysis. Protein content in each step of
purification was measured using a Bio-Rad protein assay
reagent, with bovine serum albumin as protein standard [31].
SDS/PAGE and ligand blotting
Samples obtained from affinity column were electropho-
resed on 12.5% SDS/PAGE [32] using the PhastSystem
(Amersham Pharmacia Biotech GmbH Europe). The gels
for protein profiles were stained with silver according to
Fig. 1. Schematic representation of the synthesis of melatonin–agarose
resin. The hydroxyl group of 6-hydroxymelatonin was coupled to the
epoxide group of epoxy-activated Sepharose 6B to yield melatonin–
agarose.
Ó FEBS 2003 Melatonin–calreticulin relationship (Eur. J. Biochem. 270) 833
Heukeshoven and Dernick [33]. Proteins separated by SDS/
PAGE were transferred to nitrocellulose using the Phar-
macia Semi-dry Transfer kit [34]. Briefly, the nitrocellulose
strips were incubated for 1 h at room temperature in
blocking buffer [0.4% gelatin in PBST (150 m
M
phosphate-
buffered saline, pH 7.4, containing 0.1% (v/v) Tween 20)],
followed by incubation with PBST buffer containing 10 l
M
melatonin for 1 h at 4 °C. Ligand blot analysis was carried
out using 1 : 800 dilution in PBST buffer of a specific
polyclonal antibody against melatonin (G/S/704–8483;
Stockgrand Ltd, Guildford, UK) for 2 h at room tempera-
ture. After washing three times in PBST, the nitrocellulose
membranes were incubated for 1 h with sheep peroxidase
conjugated secondary antibody (1 : 800) in PBST and then
washed again as above. The blots were finally developed
with 3,3¢-diaminobenzidine. Gels and blots were digitized
and processed by QuantiScan software (Biosoft, UK) and
the molecular masses of the polypeptides were calculated
according to their R
f
values.
Western blotting
Proteins obtained from both crude nuclear extract and
solubilized material were loaded and separated by 12.5%
SDS/PAGE, and Western blot analysis was performed
according to the procedure of Towbin et al.[34].Briefly,
separated proteins were transferred onto polyvinylidene
difluoride membranes and blocked for 1 h at room
temperature in 0.4% gelatin in PBST. Then, the gels were
incubated for 1 h at room temperature with rabbit
polyclonal antisera to calnexin and calreticulin (Sigma-
Aldrich, Spain) at 1 : 1000 in PBST. Blots were washed
three times in PBST, exposed to horseradish peroxidase-
coupled antirabbit immunoglobulin, and detected by ECL
according to the manufacturer’s protocol (Amersham
Pharmacia Biotech, Spain).
Anti-calnexin immunohistochemistry
Isolated nuclei and microsomes were used for the immu-
nohistochemical localization of calnexin in endoplasmic
reticulum (ER). The homogenates were fixed by immersion
in Formaline’s fixative (4%). After dehydration in graded
alcohol, the homogenates were embedded in paraffin and
cut into 10-lm sections. The sections were mounted on
gelatin-coated slides and processed by the peroxidase–
antiperoxidase (PAP) technique. After three 10-min rinses
in phosphate buffer, endogenous peroxidase within the
homogenates was blocked by a solution of 0.3% hydrogen
peroxidase in NaCl/P
i
at room temperature for 30 min. This
step was followed by three washes in NaCl/P
i
and incuba-
tion for 30 min in a solution of 1 : 30 goat serum in NaCl/
P
i
. Sections were treated with rabbit polyclonal antisera to
calnexin (Stressgen Biotechnologies) in serial dilutions from
1 : 200 to 1 : 5000 in NaCl/P
i
and incubated for 24 h at
room temperature in a humid atmosphere. The slides were
then rinsed in NaCl/P
i
and incubated with goat antirabbit
immunoglobulin diluted 1 : 100 in NaCl/P
i
for 1 h and then
with PAP complex diluted 1 : 100 for 1 h. The sites of
peroxidase attachment were demonstrated by incubation in
0.005% 3,3¢-diaminobenzidine tetrahydrochloride solution
in Tris/HCl buffer (50 m
M
, pH 7.6) containing 0.025%
hydrogen peroxide. Finally the sections were rinsed in
water, dehydrated and coverslipped. To ensure method
specificity, the usual controls were performed.
N-Terminal sequence analysis
Proteins separated by SDS/PAGE were transferred to
polyvinylidene difluoride and stained with Coomassie blue.
The polypeptides of 60 and 74 kDa were excised and the
first 15 N-terminal amino acid residues of each protein were
sequenced by the Protein/Peptide Micro Analytical Labor-
atory (California Institute of Technology, USA). Protein
sequences comparisons were carried out using the
FASTA
program [35]. Swiss-Prot databanks were accessed though
the GeneBank online service.
Expression and purification of fusion protein
Recombinant fusion protein glutathione S-transferase–
calreticulin (GST–calreticulin) or GST were expressed in
Escherichia coli strain BL21 (DE3)pysL (Stratagene, La
Jolla, CA, USA) using a plasmid encoding rabbit calreti-
culin provided by M. Michalak (Alberta University,
Edmonton, Canada) [36]. Rabbit and rat calreticulin share
92.57% homology. Cells were grown to late log phase and
induced to express the fusion proteins by addition of
0.25 m
M
isopropyl-1-thio-
D
-galactopyranoside for 4 h. The
cells were harvested and lysed in lysis buffer (50 m
M
Tris,
pH 7.8, 0.4
M
NaCl,10%glycerol,0.5 m
M
EDTA, complete
protease inhibitor, 0.1% Nonidet P-40) containing 1%
Triton X-100 and 350 lgÆmL
)1
lysozyme. Soluble proteins
were separated from the inclusion bodies and bacterial
debris by centrifugation at 10 000 g for 20 min at 4 °C. The
recombinant proteins were purified from the supernatant
by glutathione-Sepharose (Amersham Pharmacia Biotech
Europe GmbH) and extensively washed with NaCl/P
i
.
Matrix bound protein was used for binding assay.
2-[
125
I]Melatonin binding assay
An aliquot of 20 lL of GST-calreticulin or GST proteins
weremixedwith50m
M
Tris-HCl, pH 7.4 (6.96 m
M
CaCl
2
,
100 l
M
dithiothreitol) in a total volume of 100 lL, yielding a
final protein concentration of 200 lgÆmL
)1
. The mixture was
incubated at 37 °C for 2 h in the presence of 100 p
M
radiolabeled ligand (2-[
125
I]melatonin, 81.4 TbqÆmmol
)1
)
and the incubation was stopped adding 100 lLofcold
100% trichloroacetic acid followed by centrifugation at
45 000 g for 15 min at 4 °C. The supernatant was discarded
by aspiration, and the radioactivity on the pellets was
determined in a gamma-counter. Nonspecific binding, cal-
culated in the presence of 10 l
M
melatonin, was 12–16% of
the total binding. Kinetic parameters (K
D
and B
max
)and
IC
50
values were measured from the displacement curves
with the
LIGAND-PC
program (KELL software, Biosoft,
UK). Protein content was determined as described [31].
Statistics
Data are expressed as means ± SEM. Comparisons among
groups were made by a one-way analysis of variance
(
ANOVA
) followed by Student’s t-test.
834 M. Macı
´
as et al. (Eur. J. Biochem. 270) Ó FEBS 2003
Results
Purification by affinity chromatography
The results obtained after purification of the melatonin
receptor present in rat liver nuclei by affinity chromato-
graphy are shown in Table 1. Affinity chromatography of
crude nuclear extract (6000–8000 g) gave 0.14% of protein
(8.4–11.2 lg). The yield of the melatonin–agarose step
significantly increased when solubilized material was used as
source of melatonin receptor. A higher percentage of
purified protein was obtained from the 45 to 65% ammo-
nium sulfate fraction. This fraction yields 0.45% of protein
(2.7–3.6 lg protein) after its purification by melatonin–
agarose.
Electrophoresis analysis
Aliquots of both crude nuclear extract and solubilized
material purified by affinity chromatography were analyzed
by SDS/PAGE gel electrophoresis followed by silver
staining (Fig. 2). Crude nuclear extract shows a wide stain
ranging from 94 to 14 kDa (lanes 1 and 2). The protein
pattern was similar in samples either untreated (lane 1) or
treated with b-mercaptoethanol (lane 2). The number of
protein bands decreased with ammonium sulfate treat-
ment in solubilized material, and only two bands were
clearly identified in 45–65% ammonium sulfate samples
(lane 5). These bands, corresponding to polypeptides of 60
and 74 kDa, were also present in 25–45% (lane 4) and
0–25% (lane 3) ammonium sulfate fractions and in crude
nuclear extract samples (lanes 1 and 2). An aliquot of
molecular mass marker solution was applied as reference
(M
r
lane).
N-Terminal sequence of the p74 and p60 proteins
To analyze the primary structure of 74 and 60 kDa
polypeptides, protein microsequencing was carried out. In
order to transfer a sequenceable quantity of protein onto the
polyvinylidene difluoride, several nanomoles of protein were
loaded onto the gel prior to electrophoresis. Electroblotted
polypeptides were located by staining of the polyvinylidene
difluoride with Coomassie blue. The sequences obtained
were subjected to similarity searches in the database
network. As no sequence identity was found for the
74 kDa protein (SFLEEDRNDQPVEI) after comparing
with known protein sequences, this protein is suggested to
be a novel protein. Searching the sequence database of the
National Center of Biotechnology Information (NCBI),
the protein–protein blast program showed no similarity of
the 74 kDa protein with any other known protein to date.
Besides, there is no information in a GeneBank that may
help to identify this protein. Interestingly, the N-terminal
sequence of the first 12 residues of the 60 kDa protein
(DPAIYFKEQFLDGFA) was 100% identity to that of rat
calreticulin.
Western blotting and anticalnexin
immunohistochemistry
To identify the presence of calreticulin and to discard a
possible contamination of our preparation with ER,
Western blot analyses were performed using the antibodies
anticalreticulin and anticalnexin (Fig. 3). Lanes 1 and 5
correspond to crude nuclear extract and lanes 2–4 corres-
pond to solubilized material treated with 0–25%, 25–45%
and 45–65% ammonium sulfate, respectively. Lanes 1–4
were incubated in the presence of calreticulin antibody and
lane 5 with calnexin antibody. A positive control for
calnexin antibody is shown in lane 6, that correspond to the
microsome sample. Only one band corresponding to the
polypeptides of 60 kDa was recognized in the presence of
anticalreticulin (lanes 1–4), and this band is enriched by
25–65% ammonium sulfate precipitation. A lack of immu-
noreactive band is apparent in lane 5. The results confirm
the identity of the 60 kDa protein as calreticulin, and
exclude a contamination from ER.
To further assess whether calreticulin was not being
copurified from ER during the purification procedure,
anticalnexin immunohistochemistry was carried out in
preparations from nuclei homogenate. A fraction contain-
ing ER was also used for control purposes. The results show
a lack of immunoreactivity in the nuclei homogenates,
whereas positive immunoreactivity for anticalnexin was
found in homogenates from microsomes (data not shown).
Ligand blotting
Figure 4 demonstrates that the 74 and 60 kDa proteins
specifically bind melatonin as determined by ligand blotting
using anti-melatonin Ig. Lane 3 corresponds to crude
nuclear material and lanes 4–6 correspond to solubilized
material treated with 0–25, 25–45 and 45–65% ammonium
sulfate, respectively. Lanes 3, 4, 5 and 6 were incubated with
10 l
M
melatonin. Only the bands corresponding to the
Table 1. Purification of the melatonin receptor. Starting material refers to the amount of protein present in samples of crude nuclear extract and in
samples of solubilized material treated with different concentrations of ammonium sulfate. Affinity chromatography data shows the amount of
protein obtained after incubation of these samples with melatonin agarose. The percentage of purified proteins in relation to the protein content in
the starting material is shown in brackets.
Sample
Starting material
(lg protein)
Affinity chromatography
(lg protein)
Crude nuclear extract 6000–8000 8.4–11.2 (0.14%)
Solubilized material (Triton X-100)
0–25% ammonium sulfate precipitate 900–1200 2.2–2.9 (0.24%)
25) 45% ammonium sulfate precipitate 800–900 2.7–3.1 (0.34%)
45–65% ammonium sulfate precipitate 600–800 2.7–3.6 (0.45%)
Ó FEBS 2003 Melatonin–calreticulin relationship (Eur. J. Biochem. 270) 835
polypeptides of 74 and 60 kDa were recognized in the
presence of melatonin, thus suggesting that these proteins
bind melatonin selectively. Lanes corresponding to crude
nuclear extract or solubilized material incubated with
melatonin in the absence of anti-melatonin Ig (lane 1) or
incubated with anti-melatonin Ig in the absence of ligand
(lane 2) served as controls. Standards stained with Coo-
massie blue R were included (M
r
lane). These molecules do
not correspond to proteins such as histones which are
associated with DNA, as was further assessed by amino acid
sequencing, because they were not recognized by antibodies
against histones (data not shown).
Binding experiments
To further assess the characteristics of melatonin–calreti-
culin binding, a series of competitive experiments were
carried out. Figure 5 (left) shows a typical displacement
curve for 2-[
125
I]melatonin performed with bacterially
produced GST-calreticulin fusion proteins. The IC
50
value
was 0.97 ± 0.3 n
M
. Scatchard transformation was carried
out from competition experiments after recalculating the
specific activities (Fig. 5, left inset). Kinetic analysis of these
data yielded a K
d
of 1.08 ± 0.2 n
M
and a B
max
of 290 ± 34
fmolÆmg protein
)1
. Specific binding was undetectable in the
absence of Ca
2+
. Binding experiments in the presence of
different doses (1 n
M
to 10 m
M
) of NAS, 4-P-PDOT and
luzindole showed no competition with the radioligand.
Moreover, the binding was specific for calreticulin, as no
specific binding to bacterially produced GST protein was
detected.
Discussion
The objective of this work was to purify the nuclear
melatonin receptor elsewhere characterized in liver nuclei
[23,24], by classical protein purification approaches. From
this work, two polypeptides of 74 and 60 kDa that
specifically bind to melatonin were obtained. Luzindole
and 4-P-PDOT, two selective antagonists for the mt
1
/MT
2
subtypes of the melatonin membrane receptors [37] do not
compete with 2-[
125
I]melatonin binding to calreticulin, the
60 kDa protein. These results, together with the sequencing
Fig. 4. Ligand blotting (SDS/PAGE) of nuclear extracts purified by
affinity chromatography. Crude nuclear extract (lane 3) and solubilized
material pretreated with 0–25, 25–45 and 45–65% (lanes 4, 5 and 6,
respectively) ammonium sulfate. The blots were preincubated with
10 l
M
melatonin (lane 3, 4, 5 and 6) as described in Material and
methods. Lane 1 and 2 served as controls. The crude nuclear extract
was incubated with 10 l
M
melatonin in absence of anti-melatonin Ig
(lane 1), or incubated with the primary antibody in absence of ligand
(lane 2). Molecular mass markers stained with Coomassie blue R are
indicatedintheM
r
lane.
Fig. 2. Silver-stained SDS/PAGE gels (12.5% homogenous media) of
purified material by affinity chromatography. The gels show the dena-
tured polypeptide composition of crude nuclear extract either
untreated (lane 1) or treated with 1-mercaptoethanol (lane 2), and
solubilized material treated with ammonium sulfate at 0–25% (lane 3),
25–45% (lane 4) and 45–65% (lane 5). Molecular mass markers are
indicated in the M
r
lane.
Fig. 3. Western blotting of crude nuclear extract (lanes 1 and 5) and
solubilized material pretreated with 0–25, 25–45 and 45–65% (lanes 2, 3
and 4, respectively) ammonium sulfate. The blots were incubated with
anti-calreticulin (lanes 1–4) and anti-calnexin Igs (lane 5) as described
in Material and methods. Lane 6 corresponds to a positive control for
calnexin antibody in microsomes.
836 M. Macı
´
as et al. (Eur. J. Biochem. 270) Ó FEBS 2003
data, suggest that the proteins purified in this study
represent a new class of specific binding sites for melatonin.
The proteins present in the crude nuclear extract,
precipitated with ammonium sulfate, allowed us to increase
the efficiency of the receptor purification by decreasing the
number of proteins present in the sample. We found that
maximal calreticulin activity was obtained in samples
precipitated with 45–65% ammonium sulfate, i.e. in the
similar precipitating fraction as previously described [38].
However, the fraction obtained with 25–45% ammonium
sulfate precipitation also has high content of calreticulin and
so, the largest yield of melatonin receptors (0.79%) was
obtained after affinity chromatography of samples precipi-
tated with 25–65% ammonium sulfate. In addition, the
number of proteins separated by SDS/PAGE and stained
with silver nitrate was significantly reduced after ammonium
sulfate treatment. The results suggest that these sample
pretreatments before affinity chromatography not only
increased the percentage of receptor obtained but also
removed a large number of proteins that might interfere
with the purification procedure itself.
The development of the melatonin–agarose resin allowed
us to improve the purification procedure of the melatonin
nuclear receptor. Criteria used for the validation of other
affinity resins [39] strongly suggest that melatonin–agarose
interacts with solubilized receptors in a specific manner.
Purification achieved with melatonin–agarose is similar to
that achieved with affinity resins developed for the purifi-
cation of other receptors [40]. The purified proteins obtained
after affinity chromatography show pharmacological pro-
perties compatible with a receptor of melatonin. These data
support the utility of the melatonin–agarose resin to purify
the melatonin nuclear receptor and suggest that large-scale
purification may be now feasible. Electrophoresis and
Western blot analysis of the samples purified by affinity
chromatography revealed the presence of two proteins
corresponding to molecular weights of 74 and 60 kDa.
The N-terminal amino acid sequence of the purified
proteins was searched in protein databases for homology
identity. Regarding the 74 kDa protein, no proteins with a
similar sequence were found, suggesting that this polypep-
tide is a novel, formerly unknown protein. It was, however,
an unexpected finding that the N-terminal amino acid
sequence of the 60 kDa protein showed considerable
sequence homology with rat calreticulin. It is interesting
that calreticulin, a highly acidic protein, moves at about
60–65 kDa on SDS/PAGE [41], although the deduced
molecular mass from the amino acids is 46 kDa. A 60-kDa
polypeptide obtained after SDS/PAGE of a 55–70%
ammonium sulfate precipitate of the HeLa cell cytosol
was also identified as calreticulin by mass spectrometry [38].
Thus, the similarity of our purification methodology
compared with that used by these authors, the molecular
mass of the polypeptide obtained by SDS/PAGE, and the
sequence analysis results, strongly suggest that the 60 kDa
protein purified by us is calreticulin.
The melatonin binding to calreticulin is highly specific
and displays nanomolar affinity. The specificity of this
biding is also supported because NAS, the metabolic
precursor of melatonin with certain degree of affinity for
other melatonin binding sites [24], does not interfere with
the melatonin binding. Moreover, the presence of
4-P-PDOT and luzindole does not interfere with the binding
of melatonin to calreticulin. These results suggest a highly
specific binding of melatonin to calreticulin, although
further experiments with saturation studies should be
carried out to assess that these binding sites can be
saturated, thus confirming the existence of functional
binding of melatonin to calreticulin. The data strongly
suggests a new class of protein binding site for melatonin
and suggests that calreticulin is a target for the intracellular
action of melatonin.
Calreticulin is a ubiquitous and highly conserved Ca
2+
-
binding protein of the ER that could be regulated through
intracellular signaling pathways involving Ca
2+
binding
[42]. The protein is multifunctional and may play an
important role in the modulation of a variety of cellular
processes. These functions include chaperon activity, con-
trol of intracellular Ca
2+
homeostasis, and regulation of cell
adhesiveness by interacting with the integrins at the
cytoplasmatic site of the plasma membrane. Surprisingly,
calreticulin controls the steroid-sensitive gene expression
Fig. 5. Binding of 2-[
125
I]melatonin to calreti-
culin. (A) Competition experiments were per-
formed with recombinant calreticulin (GST–
calreticulin) and increasing concentrations of
nonlabeled melatonin. Results were expressed
as the percentage of specifically bound
2-[
125
I]melatonin. Inset: Scatchard plot of the
data in (A) showing the binding kinetics of
melatonin to GST–calreticulin. (B) Values of
B
max
of melatonin binding to GST–calreti-
culin in the presence (CRT + Ca
2+
)and
absence(CRT)ofCa
2+
, and to GST protein.
Melatonin, d;NAS,s; 4-P-PDOT, .;
luzindole, h.*P < 0.001.
Ó FEBS 2003 Melatonin–calreticulin relationship (Eur. J. Biochem. 270) 837
[43,44]. This was anunexpected finding, as calreticulin is an
ER-resident protein [45] and steroid receptors are found
either in the cytoplasm or in the nucleus.
Several pieces of evidence suggest a parallel between
calreticulin and calmodulin in nuclear melatonin signaling.
Melatonin binds both calmodulin and calreticulin only in
the presence of Ca
2+
[46]. Calreticulin mediates nuclear
export of the glucocorticoid receptor, and overexpression of
calreticulin antagonizes nuclear receptor-dependent tran-
scriptional activation [38]. Melatonin protects against
glucocorticoid-induced apoptosis regulating glucocorticoid
receptor expression [47]. Calreticulin specifically interacts
with the first zinc finger of different nuclear receptors. Based
on this feature, it was shown that calreticulin interacts with
amino acids 206–211 of the DNA binding domain region of
estrogen receptor alpha (ERa), reversing ERa inhibition of
invasion in vitro [48]. Calmodulin also modulates ERa
interacting with amino acids 290–310 of this receptor [49],
whereas melatonin–calmodulin interaction blocks the acti-
vation of estrogen receptor for DNA binding [50]. Thus, the
oncostatic effects of melatonin against ERa activation may
depend on its binding to calmodulin and calreticulin,
preventing both the binding of ERa to DNA and its
proliferative effects.
The problem of calreticulin localization into the cell
continues. Calreticulin-like immunoreactivity was detected
in the nucleus of some cells, although it seems that it is not a
nuclear resident protein [45,51]. An explanation for these
contradictions may depend on the purification methodo-
logy. In fact, resident nuclear proteins are associated with
the Triton-insoluble nuclear fractions, whereas the Triton-
soluble fractions contain proteins of ER origin [52].
Michalak [45] identified 60-kDa calreticulin in the Triton
X-100 soluble fraction of purified nuclei, which includes the
solubilized outer nuclear membrane containing proteins of
the ER, but not in the Triton-insoluble fraction containing
nuclear material surrounded by the inner nuclear mem-
brane. These results suggest that calreticulin is not a resident
nuclear protein. Other reports failed to identify calreticulin
in the cytosol, suggesting that the ER, but not the cytosol
form of calreticulin is responsible for inhibition of gluco-
corticoid receptor-mediated gene expression [44,45,53,54], a
proposed function for this protein. However, in vitro DNA-
binding assays indicated that recombinant calreticulin could
inhibit DNA binding by steroid receptors, suggesting that
the effect of calreticulin on nuclear hormone receptor
transactivation might be direct [48]. Experimental evidence
exists supporting both nuclear [53] and cytosolic [38,54,55]
localization of calreticulin. These data provide evidence for
two pools of calreticulin, the first contained within the
lumen of the ER, and the second contained within the
cytosol. Our data show that nuclei homogenates are lacking
calnexin, a marker for ER [56], but that they do contain
calreticulin. Therefore, our procedure for nuclear protein
purification started from a material lacking ER contamin-
ation, suggesting that the calreticulin found in our material
does not come from this localization and that it was
associated with the nuclei.
It seems that, although it is not a nuclear resident protein,
calreticulin may localize in the nucleus. The mechanism(s)
by which calreticulin molecules are imported into, and
retained in, the nucleus are unknown. It is unclear whether
nuclear localization of calreticulin is determined by its
simple exclusion from the ER, possibly due to elimination of
its N-terminal signal sequence, or by its retrotranslocation
from the endoplasmic reticulum to the cytoplasm. The
classical view of strict protein compartmentalization has
now been challenged, and it is thought that proteins may
shuttle between the nuclear and cytoplasmic compartments
[57]. Calreticulin may have a similar behavior to localize in
distinct subcellular compartments, acting independently on
compartment-specific targets.
These data may suggest that the interaction between
melatonin and calreticulin (and calmodulin) could be of
physiological importance in regulating the activity of a
broad spectrum of nuclear receptors [38]. This hypothesis is
further supported because the high melatonin-calreticulin
binding affinity, which correlates well with the melatonin
concentration in nucleus [18,24]. Therefore, melatonin
might be a mechanism involved in importing and/or
retaining calreticulin in the nucleus. Melatonin–calreticulin
interaction also can be related to the balance of ligand-
induced import and calreticulin-dependent export, provi-
ding the cell with a nuclear transport-based mechanism.
Based on these findings, it is necessary to re-evaluate our
current understanding of the molecular pathways of mela-
tonin actions.
Acknowledgements
We thank Dr M. Michalak for providing the plasmid which encode
GST-calreticulin and Dr M. Martı
´
n for the binding experiments. We
also thank Dr C. Carlberg for helpful suggestions. This work was
supported by the CICYT grant SAF98 : 0156 and Junta de Andalucı
´
a
(CTS-101). M. Macı
´
as is a fellow from the Programa de Formacion de
Personal Investigador, Ministerio de Educacion y Cultura, Spain.
References
1. Kondo, T., Mori, T., Lebedeva, N.V., Aoki, S., Ishiura, M. &
Golden, S.S. (1997) Circadian rhythms in rapidly dividing cya-
nobacteria. Science 275, 224–227.
2. Hardeland, R. & Fuhrberg, B. (1996) Ubiquitous melatonin –
presence and effects in unicells, plants and animals. Trends Comp.
Biochem. 2, 25–44.
3. Reiter, R.J. (1991) Pineal gland. Interface between the photo-
periodic environment and the endocrine system. Trends Edocrinol.
Metab. 2, 13–19.
4. Huether, G. (1993) The contribution of extrapineal sites of mela-
tonin synthesis to circulating melatonin levels in higher verte-
brates. Experientia 49, 665–670.
5. Tamarkin, L., Baird, C.J. & Almeida, O.F.X. (1985) Melatonin: a
coordinating signal for mammalian reproduction? Science 227,
714–720.
6. Reiter, R.J. (1995) Functional pleiotropy of the neurohormone
melatonin: Antioxidant protection and neuroendocrine regula-
tion. Front. Neuroendocrinol. 16, 383–415.
7. Liebmann, P.M., Wolfler, A., Felsner, P., Hofer, D. & Schauen-
stein, K. (1997) Melatonin and the immune system. Int. Arch.
Allergy Immunol. 112, 203–211.
8. Cos,S.,Fernandez,F.&Sa
´
nchez-Barcelo
´
, E.J. (1996) Melatonin
inhibits DNA synthesis in MCF-7 human breast cancer cells
in vitro. Life Sci. 58, 2447–2453.
9. Sainz, R.M., Mayo, J.C., Uria, H., Kotler, M., Antolin, I.,
Rodriguez, C. & Mene
´
ndez-Pelaez, A. (1995) The pineal
838 M. Macı
´
as et al. (Eur. J. Biochem. 270) Ó FEBS 2003
neurohormone melatonin prevents in vivo and in vitro apoptosis in
thymocytes. J. Pineal Res. 19, 178–188.
10. Reiter, R.J., Melchiorri, D., Sewerynek, E., Poeggeler, B., Barlow-
Walden,L.,Chuang,J.I.,Ortiz,G.G.&Acun
˜
a-Castroviejo, D.
(1995) A review of the evidence supporting melatonin’s role as an
antioxidant. J. Pineal Res. 18, 1–11.
11. Reiter, R.J. (1998) Oxidative damage in the central nervous sys-
tem: protection by melatonin. Progr. Neurobiol. 56, 359–384.
12. Martı
´
n, M., Macı
´
as, M., Escames, G., Leo
´
n, J. & Acun
˜
a-
Castroviejo, D. (2000) Melatonin but not vitamins C and E
maintains glutathione homeostasis in t-butyl hydroperoxide-
induced mitochondrial oxidative stress. FASEB J. 14, 1677–1679.
13. Acun
˜
a-Castroviejo, D., Martı
´
n, M., Macı
´
as, M., Escames, G.,
Leo
´
n, J., Khaldy, H. & Reiter, R.J. (2001) Melatonin,
mitochondria and cellular bioenergetics. J. Pineal Res. 30, 65–74.
14. Ebisawa, T., Karne, S., Lerner, M.R. & Reppert, S.M. (1994)
Expression cloning of a high-affinity melatonin receptor from
Xenopus dermal melanophores. Proc. Natl Acad. Sci. USA 91,
6133–6137.
15. Reppert, S.M., Weaver, D.R. & Ebisawa, T. (1994) Cloning and
characterization of a mammalian melatonin receptor that medi-
ates reproductive and circadian responses. Neuron 13, 1177–1185.
16. Reppert, S.M., Godson, C., Mahle, C.D., Weaver, D.R. & Slau-
genhaupt, S.A. (1995) Molecular characterization of a second
melatonin receptor expressed in human retina and brain: the Mel
1b
melatonin receptor. Proc.NatlAcad.Sci.USA92, 8734–8738.
17. Reppert, S.M., Weaver, D.R. & Godson, C. (1996) Melatonin
receptors step into the light: cloning and classification of subtypes.
Trends Pharmacol. Sci. 17, 100–102.
18. Mene
´
ndez-Pelaez, A. & Reiter, R.J. (1993) Distribution of mela-
tonin in mammalian tissues: The relative importance of nuclear
versus cytosolic localization. J. Pineal Res. 15, 59–69.
19. Antolin, I., Rodriguez, C., Sainz, R.M., Mayo, J.C., Uria, H.,
Kotler, M.L., Rodriguez-Colunga, M.J., Tolivia, D. & Mene
´
ndez-
Pelaez, A. (1996) Neurohormone melatonin prevents cell damage:
effect on gene expression for antioxidant enzymes. FASEB J. 10,
882–890.
20. Crespo, E., Macı
´
as,M.,Pozo,D.,Escames,G.,Martı
´
n, M.,
Vives, F., Guerrero, J.M. & Acun
˜
a-Castroviejo, D. (1999) Mela-
tonin inhibits expression of the inducible NO synthase II in liver
and lung and prevents endotoxemia in lipopolysaccharide-induced
multiple organ dysfunction syndrome in rats. FASEB J. 13, 1537–
1546.
21. Garcı
´
a-Maurin
˜
o, S., Gonzalez-Haba, M.G., Calvo,J.R., Goberna,
R. & Guerrero, J.M. (1998) Involvement of nuclear binding sites
for melatonin in the regulation of IL-2 and IL-6 production by
human blood mononuclear cells. J. Neuroimmunol. 92, 76–84.
22. Slominski, A. & Pruski, D. (1993) Melatonin inhibits proliferation
and melanogenesis in rodent melanoma cells. Exp Cell Res. 206,
189–194.
23. Acun
˜
a-Castroviejo, D., Pablos, M.I., Mene
´
ndez-Pela
´
ez,A.&
Reiter, R.J. (1993) Melatonin receptors in purified cell nuclei of
liver. Res. Comm. Chem. Pathol. Pharmacol. 82, 253–256.
24. Acun
˜
a-Castroviejo, D., Reiter, R.J., Mene
´
ndez-Pelaez, A., Pablos,
M.I. & Burgos, A. (1994) Characterization of high-affinity mela-
tonin binding sites in purified cell nuclei of rat liver. J. Pineal Res.
16, 100–112.
25. Becker-Andre
´
, M., Wiesenberg, I., Schaeren-Wiemers, N., Andre
´
,
E., Missbach, M., Saurat, J H. & Carlberg, C. (1994) Pineal gland
hormone melatonin binds and activates an orphan of the nuclear
receptor superfamily. J. Biol. Chem. 269, 28531–28534.
26. Wiesenberg, I., Missbach, M., Kahlen, J P., Schra
¨
der, M. &
Carlberg, C. (1995) Transcriptional activation of the nuclear
receptor RZR by the pineal gland hormone melatonin and iden-
tification of CGP 52608 as a synthetic ligand. Nucleic Acids Res.
23, 327–333.
27. Steinhilber, D., Brungs, M., Werz, O., Wiesenberg, I., Danielsson,
C., Kahlen, J P., Nayeri, S., Schra
¨
der, M. & Carlberg, C. (1995)
The nuclear receptor for melatonin represses 5-lipoxygenase gene
expression in human B lymphocytes. J. Biol. Chem. 270, 7037–
7040.
28. Blum, M., McEwens, B.S. & Roberts, J.L. (1987) Transcriptional
analysis of tyrosine hydroxylase gene expression in the tuber-
oinfundibular dopaminergic neurons of the rat arcuate nucleus
after estrogen treatment. J. Biol. Chem. 262, 817–821.
29. Englard, S. & Seifter, S. (1990) Precipitation techniques. Methods
Enzymol. 182, 285–300.
30. Anonymous. (1988) Affinity Chromatography. Principles and
Methods. Pharmacia LKB Biotechnology, Uppsala, Sweden.
31. Bradford, M. (1976) A rapid and sensitive method for the quan-
titation of microgram quantities of protein utilizing the principle
of protein-dye binding. Anal. Biochem. 72, 248–254.
32. Laemmli, U.K. (1970) Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature 227, 680–
685.
33. Heukeshoven, J. & Dernick, R. (1985) Simplied method for silver
staining of proteins in polyacrylamide gels and mechanism of sil-
ver staining. Electrophoresis 6, 103–112.
34. Towbin, H., Staeheling, T. & Gordon, J. (1979) Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedure and some apllications. Proc. Natl Acad. Sci.
USA 76, 4354–4350.
35. Pearson, W.R. & Lipman, D.J. (1988) Improved tools for biolo-
gical sequence comparison. Proc. Natl Acad. Sci. USA 85, 2444–
2448.
36. Baksh, S. & Michalak, M. (1991) Expression of calreticulin in
Escherichia coli and identificatmon of its Ca2+ binding domains.
J. Biol. Chem. 266, 21458–21465.
37. Dubocovich,M.L.,Yun,K.,Al-Ghoul,W.M.,Benloucif,S.&
Masana, M.I. (1998) Selective MT2 melatonin receptor anta-
gonists block melatonin-mediated phase advances of circadian
rhythms. FASEB J. 12, 1211–1220.
38. Holaska, J.M., Black, B.E., Love, D.C., Hanover, J.A., Lesyk, J.
& Paschal, B.M. (2001) Calreticulin is a receptor for nuclear
export. J. Cell Biol. 152, 127–140.
39. Caron,M.G.,Srinivasan,Y.,Pitha,J.,Kociolek,K.&Lefkowitz,
J.R. (1979) Affinity chromatography of the b-adrenergic receptor.
J. Biol. Chem. 254, 2923–2927.
40. Lomasney, J.W., Leeb-Lundberg, L.M.F., Cotecchia, S., Regan,
J.W., DeBernardis, J.F., Caron, M.G. & Lefkowitz, R.J. (1986)
Mammalian a
1
-adrenergic receptor. Purification and characteri-
zation of the native receptor ligand binding subunit. J. Biol. Chem.
261, 7710–7716.
41. Milner, R.E., Baksh, S., Shemanko, C., Carpenter, M.R.,
Smillie, L., Vance, J.E., Opas, M. & Michalak, M. (1991) Calre-
ticulin, and not calsequestrin, is the major calcium binding protein
of smooth muscle sarcoplasmic reticulum and liver endoplasmic
reticulum. J. Biol. Chem. 266, 7155–7165.
42. Krause, K.H. & Michalak, M. (1997) Calreticulin. Cell 88, 439–
443.
43. Burns, K., Duggan, B., Atkinson, E.A., Famulski, K.S.,
Nemer, M., Bleackley, R.C. & Michalak, M. (1994) Modulation
of gene expression by calreticulin binding to the glucocorticoid
receptor. Nature 367, 476–480.
44. Dedhard, S., Rennie, P.S., Shago, M., Hagesteijn, C.Y.L.,
Yang, H., Filmus, J., Hawley, R.G., Bruchovsky, N., Cheng, H.,
Matusik, R.J. & Giguere, V. (1994) Inhibition of nucleare hor-
mone receptor activity by calreticulin. Nature 367, 480–483.
45. Michalak, M., Burns, K., Andrin, C., Mesaeli, N., Jass, G.H.,
Busaan, J.L. & Opas, M. (1996) Endoplasmic reticulum form
of calreticulin modulates glucocorticoid-sensitive gene expression.
J. Biol. Chem. 271, 29436–29445.
Ó FEBS 2003 Melatonin–calreticulin relationship (Eur. J. Biochem. 270) 839
46. Leo
´
n, J., Macı
´
as, M., Escames, G., Camacho, E., Khaldy, H.,
Martı
´
n,M.,Espinosa,A.,Gallo,M.A.&Acun
˜
a-Castroviejo, D.
(2000) Structure-related inhibition of calmodulin-dependent
nNOS activity by melatonin and synthetic kynurenines. Mol.
Pharmacol. 58, 967–975.
47. Sainz, R.M., Mayo, J.C., Reiter, R.J., Antolin, I., Esteban, M.M.
&Rodrı
´
guez, C. (1999) Melatonin regulates glucocorticoid
receptor: An answer to its antiapoptotic action in thymus. FASEB
J. 13, 1547–1556.
48. Platet, N., Cunat, S., Chalbos, D., Rochefort, H. & Garcia, M.
(2000) Unliganded and liganded estrogen receptors protect against
cancer invasion via different mechanisms. Mol. Endocrinol. 14,
999–1009.
49. Garcia Pedrero, J.M., Del Ri, B., Martinez-Campa, C.,
Muramatsu, M., Lazo, P.S. & Ramos, S. (2002) Calmodulin is a
selective modulator of estrogen receptors. Mol. Endocrinol. 16,
947–960.
50. Garcia Rato, A., Garcia Pedrero, J.M., Martinez, A., Del Rio, B.,
Lazo, P.S. & Ramos, S. (1999) Melatonin blocks the activation of
estrogen receptor for DNA binding. FASEB J. 13, 857–868.
51. Michalak, M., Corbett, E.F., Mesaeli, N., Nakamura, K. &
Opas, M. (1999) Calreticulin: one protein, one gene, many func-
tions. Biochem. J. 344, 281–292.
52. Blobel, G. & Potter, V.R. (1966) Nuclei from rat liver: isolation
method that combines purity with high yield. Science 154, 1662–
1665.
53. Roderick, H.L., Campbell, A.K. & Llewellyn, D.H. (1997)
Nuclear localisation of calreticulin in vivo is enhanced by its
interaction with glucocorticoid receptors. FEBS Lett. 405, 181–
185.
54. Jethmalani, S.M., Henle, K.J., Gazitt, Y., Walker, P.D. & Wang,
S.Y. (1997) Intracellular distribution of heat-induced stress gly-
coproteins. J. Cell Biochem. 66, 98–111.
55. Yoon, G.S., Lee, H., Jung, Y., Yu, E., Moon, H.B., Song, K. &
Lee, I. (2000) Nuclear matrix of calreticulin in hepatocellular
carcinoma. Cancer Res. 60, 1117–1120.
56. Wada, I., Rindress, D., Cameron, P.H., Ou, W.J., Doherty, J.J.,
Louvard, D., Bell, A.W., Dignard, D., Thomas, D.Y. & Bergeron,
J.J. (1991) SSR alpha and associated calnexin are major calcium
binding proteins of the endoplasmic reticulum membrane. J. Biol.
Chem. 266, 19599–19610.
57. Yang,L.,Guerrero,J.,Hong,H.,DeFranco,D.B.&Stallcup,
M.R. (2000) Interaction of the tau2 transcriptional activation
domain of glucocorticoid receptor with a novel steroid receptor
coactivator, Hic-5, which localizes to both focal adhesions and the
nuclear matrix. Mol. Biol. Cell 11, 2007–2018.
840 M. Macı
´
as et al. (Eur. J. Biochem. 270) Ó FEBS 2003
. the antibodies anticalreticulin and anticalnexin (Fig. 3). Lanes 1 and 5 correspond to crude nuclear extract and lanes 2–4 corres- pond to solubilized material treated with 0–25%, 25–45% and. Calreticulin–melatonin An unexpected relationship Manuel Macı ´ as 1 , Germaine Escames 1 , Josefa Leon 1 , Ana Coto 3 , Younes Sbihi 2 , Antonio Osuna 2 and Darı ´ o Acun ˜ a-Castroviejo 1 1 Departamento. either untreated (lane 1) or treated with 1-mercaptoethanol (lane 2), and solubilized material treated with ammonium sulfate at 0–25% (lane 3), 25–45% (lane 4) and 45–65% (lane 5). Molecular mass